Search Results - "Mun, Elijah J."

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis by Ioannou, George N, Green, Pamela, Lowy, Elliott, Mun, Elijah J, Berry, Kristin

    Published in PloS one (27-09-2018)
    “…Hepatocellular carcinoma (HCC) risk is high in cirrhosis. We sought to describe differences in HCC risk, predictors and trends over time according to etiology…”
    Get full text
    Journal Article
  2. 2

    Tumor-Treating Fields: A Fourth Modality in Cancer Treatment by Mun, Elijah J, Babiker, Hani M, Weinberg, Uri, Kirson, Eilon D, Von Hoff, Daniel D

    Published in Clinical cancer research (15-01-2018)
    “…Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant…”
    Get full text
    Journal Article
  3. 3

    Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C by Ioannou, George N., Green, Pamela K., Beste, Lauren A., Mun, Elijah J., Kerr, Kathleen F., Berry, Kristin

    Published in Journal of hepatology (01-11-2018)
    “…[Display omitted] •We developed and validated models to estimate HCC risk after antiviral treatment for HCV.•Using these models may improve HCC screening…”
    Get full text
    Journal Article
  4. 4

    Recent advances and current challenges in endoscopic resection with the full-thickness resection device by Mun, Elijah J, Wagh, Mihir S

    Published in World journal of gastroenterology : WJG (07-07-2023)
    “…Endoscopic full-thickness resection (EFTR) has emerged as a viable technique in the management of mucosal and subepithelial lesions of the gastrointestinal…”
    Get full text
    Journal Article
  5. 5

    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk by Mun, Elijah J, Green, Pamela, Berry, Kristin, Ioannou, George N

    “…BACKGROUND AND AIMSIt is unclear whether there are differences between direct-acting antivirals (DAAs) for hepatitis C virus in risk of hepatocellular…”
    Get full text
    Journal Article
  6. 6